OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Steriline will be exhibiting its vial filling and capping machine (VFCM100) under double-wall isolator for aseptic filling at CPHI 2022 in Frankfurt, Germany, on Nov. 1–3, 2022.
Steriline, a European manufacturer of complete lines for the aseptic processing of injectable products, announced on Nov. 1, 2022, that it will be showcasing a vial filling and capping machine (VFCM100) under double-wall isolator at CPHI 2022 being held in Frankfurt, Germany, on Nov. 1–3, 2022. The VFCM100 under double-wall isolator is a solution developed to increase contract development manufacturing organization (CDMO) production capacity for COVID-19 vaccines.
The machine can reach a production capacity of 6000 pieces/hour, according to a company press release. It was developed for injectable drugs and is equipped with four peristaltic pumps, allowing for potentially an infinite filling capacity and a 100% check-weighing. The machine can handle glass vials from 2 mL to 100 mL, and, with an easy format change, can also handle plastic vials.
Meanwhile, the double-wall isolator guarantees sterility throughout the whole aseptic filling process, protecting not only personnel from contact with the product but also minimizing the risk of product contamination. Once vials are capped, they are moved via conveyor belt into a printer where every cap is marked with the relative batch details for tracking purposes. An added benefit of the machine are its space-saving sizes, which comfortably fit in the available processing area, according to the press release.
Although an increase in demand for these types of machines has been seen in Europe and other continents, this increase in demand was not due only to COVID-19 vaccines but also to the manufacture of other drugs. As a result, several companies have expressed plans to convert the VFCM100 under double-wall isolator to the production of other products, such as biotech drugs, over the course of the next few years, according to Federico Fumagalli, chief commercial officer, Steriline, in the press release.